Toward a rational design of multitarget-directed antioxidants: Merging memoquin and lipoic acid molecular frameworks

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7883-7886

  Bolognesi, Maria Laura ^a   Cavalli, Andrea ^a,b   Bergamini, Christian ^a   Fato, Romana ^a   Lenaz, Giorgio ^a   Rosini, Michela ^a   Bartolini, Manuela ^a   Andrisano, Vincenza ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANTIOXIDANT; CHOLINESTERASE; LIPOCRINE; MEMOQUIN; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CELL LINE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; GLIOMA CELL; HUMAN; HUMAN CELL; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN AGGREGATION;

ALKANES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIOXIDANTS; CELL LINE, TUMOR; DRUG DESIGN; ELECTRON TRANSPORT; ETHYLAMINES; HUMANS; LIGANDS; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; SUBMITOCHONDRIAL PARTICLES; THIOCTIC ACID; UBIQUINONE;

EID: 72249110242     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901123n     Document Type: Article

References (23)

1. Smith, M. A.; Perry, G.; Pryor, W. A. Causes and consequences of oxidative stress in Alzheimer's disease. Free Radical Biol. Med. 2002, 32, 1049.
2. Chong, Z. Z.; Li, F.; Maiese, K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 2005, 75, 207-246.
3. Zhu, X.; Su, B.; Wang, X.; Smith, M. A.; Perry, G. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 2007, 64, 2202-2210.
4. Xiong, K.; Cai, H.; Luo, X. G.; Struble, R. G.; Clough, R. W.; Yan, X. X. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp. Brain Res. 2007, 181, 435-446.
5. Coma, M.; Guix, F. X.; Ill-Raga, G.; Uribesalgo, I.; Alameda, F.; Valverde, M. A.; Munoz, F. J. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol. Aging 2008, 29, 969-980.
6. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol. Med. 1997, 23, 134-147.
7. Wadsworth, T. L.; Bishop, J. A.; Pappu, A. S.; Woltjer, R. L.; Quinn, J. F. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J. Alzheimer's Dis. 2008, 14, 225-234. (Pubitemid 352040040)
8. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Munch, G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol. Ther. 2007, 113, 154-164.
9. Liu, J. The effects and mechanisms of mitochondrial nutrient alphalipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem. Res. 2008, 33, 194-203.
10. Cavalli, A.; Bolognesi,M. L.;Minarini, A.; Rosini,M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
11. Bolognesi, M. L.; Rosini, M.; Andrisano, V.; Bartolini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C. MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. Curr. Pharm. Des. 2009, 15, 601-613.
12. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem., Int. Ed. 2007, 46, 3689-3692.
13. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48, 360-363.
14. Ono, K.; Hirohata, M.; Yamada, M. Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun. 2006, 341, 1046-1052.
15. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem. Biophys. Res. Commun. 2005, 330, 111-116.
16. Kozlov, A. V.; Gille, L.; Staniek, K.; Nohl, H. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch. Biochem. Biophys. 1999, 363, 148-154.
17. Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem. 2007, 50, 4882-4897.
18. Reddy, P. H.; Beal, M. F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008, 14, 45-53.
19. Raina, A. K.; Templeton, D. J.; Deak, J. C.; Perry, G.; Smith, M. A. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Rep. 1999, 4, 23-27.
20. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multitarget-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009, 6, 152-162.
21. Frid, P.; Anisimov, S. V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 2007, 53, 135-160.
22. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discovery Today 2007, 12, 156-160.
23. Korcsmaros, T.; Szalay, M. S.; Böde, C.; Kovacs, I. A.; Csermely, P. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discovery 2007, 2, 1-10.